Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline

about

Management of Potential Long-Term Toxicities in Breast Cancer Patients.

P2860

Q39305824-EB49A87D-AE88-4CFA-B9B2-B31187C8493C

P2860

Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline

Item

http://www.wikidata.org/entity/Q35750472

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Bone Health in Patients with B ...... dence-Based Canadian Guideline

@ast

Bone Health in Patients with B ...... dence-Based Canadian Guideline

@en

type

Item

label

Bone Health in Patients with B ...... dence-Based Canadian Guideline

@ast

Bone Health in Patients with B ...... dence-Based Canadian Guideline

@en

prefLabel

Bone Health in Patients with B ...... dence-Based Canadian Guideline

@ast

Bone Health in Patients with B ...... dence-Based Canadian Guideline

@en

P1476

Bone Health in Patients with B ...... dence-Based Canadian Guideline

@en

P2093

Alexander H G Paterson

http://www.w3.org/2001/XMLSchema#string

Melissa A Shea-Budgell

http://www.w3.org/2001/XMLSchema#string

P2860

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

Denosumab: RANKL inhibition in the management of bone loss

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Reviewing manuscripts for Archives of Pediatrics & Adolescent Medicine.

Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.

American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

Clinical features of metastatic bone disease and risk of skeletal morbidity.

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

P304

283-301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/JCM2040283

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281847925

http://www.w3.org/2001/XMLSchema#string

P698

26237149

http://www.w3.org/2001/XMLSchema#string

P932

4470150

http://www.w3.org/2001/XMLSchema#string

Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline

about

P2860

P2860

Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932